Completed Cancer NIHR-supported project Digestion, Kidneys & Other Organs

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)

Funder NIHR (part of DHSC)
Recipient organisation NIHR Bristol Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period May 2025 — Dec 2025

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Kushala Abeysekera (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)
EMERALD: An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation
RTX001-002 Emerald : An open-label Phase 1/2 multicentre study to evaluate the safety, tolerability and efficacy of RTX001 autologous macrophages in participants with liver cirrhosis who have hepatic decompensation (EMERALD).
An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD) (the follow on study from OPAL)
EMERALD An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (the follow on study from OPAL)

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.